An NCCN survey taken during the period of congressional debate over new federal healthcare legislation, reports how oncology professionals feel about the possible repeal and replacement of the ACA.
FDA Updates Fludarabine Phosphate Labeling in Chronic Lymphocytic Leukemia
The updated labeling also includes new information on the recommended dosage of fludarabine phosphate when given with cyclophosphamide and rituximab.
Collaboration Fosters Treatment Advancements for Young Lymphoma Populations
A leader from the adolescent and young adult lymphoma space discusses how collaboration between adult and pediatric oncologists has transformed the field.
Multiple Myeloma Experts Face Off on Sequencing Therapy Options
Experts in multiple myeloma gathered to debate current treatment options in the space during a recent Face Off.
Educating Patients and Clinicians on End-of-Life Care and Discussions
Kelley A. Rone, DNP, RN, AGNP-c, provides perspective on approaching end-of-life conversations with patients with GI cancers.
EU Approval Recommended for Repotrectinib in ROS1+ NSCLC, NTRK+ Solid Tumors
Results from the TRIDENT-1 and CARE trials, which showcased durable activity and robust responses with repotrectinib, supported the recommendation.
Subcutaneous Pembrolizumab/Chemo Meets Pharmacokinetic Endpoints in NSCLC
For patients with NSCLC, subcutaneous pembrolizumab appeared noninferior vs intravenous pembrolizumab for study end points when combined with chemotherapy.